In addition, a pan-cancer analysis demonstrated that FCRLB was up-regulated in a variety of cancers, such as bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma (CESC), cholangiocarcinoma (CHOL), esophageal carcinoma (ESCA), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and stomach adenocarcinoma (STAD), as shown in Figure 2G. Here, FCRLB is linked to squamous cell lung carcinoma.